Double hit lymphoma: How do we define it and how do we treat it?

被引：18

作者：

Merron, Bridgin ^{[1
,3
]}

Davies, Andrew ^{[2
]}

机构：

[1] Univ Southampton, Southampton Clin Trials Unit, Southampton Gen Hosp, Mailpoint 131,Tremona Rd, Southampton SO16 6YD, Hants, England

[2] Southampton Gen Hosp, Fac Med, Canc Sci Div, Canc Res UK Ctr, Somers Canc Res Bldg,Mailpoint 824, Southampton SO16 6YD, Hants, England

[3] Antrim Area Hosp, Haematol Dept, Bush Rd, Antrim BT41 2RL, North Ireland

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2018年 / 31卷 / 03期

关键词：

Double -hit lymphoma; High grade lymphoma; Diffuse large B-cell lymphoma; MYC; BCL2; BCL6; PROGRESSION-FREE SURVIVAL; DOUBLE-EXPRESSER; MYC; BCL2; VENETOCLAX; OUTCOMES; IMPACT; DLBCL; IMMUNOCHEMOTHERAPY; CLASSIFICATION;

D O I：

10.1016/j.beha.2018.07.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Double/triple hit lymphoma is recognised as a distinct entity within the heterogeneous group of high grade B-cell lymphomas, accounting for between 5 and 10% of cases of diffuse large B-cell lymphoma. Under the WHO 2016 it is now known as high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6. When treated with standard chemotherapy it has a poor outcome. There is currently no standard of care for the management of this condition. Diagnosing double hit lymphoma requires identification of translocations of MYC and BCL2 and/or BCL6. This review will discuss the role of stratification to screen cases based on immunohistochemical profiling as a viable option. Treatment options in the frontline and relapsed setting will be reviewed based on the current literature. Recognition of the risk of CNS involvement and how best to manage this will be discussed. Future considerations and current research will be described.

引用

页码：233 / 240

页数：8

共 37 条

[1]

Aggarwal A, 2016, Blood, V128, P5396

[2] The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism [J].

Anderson, Mary Ann ;

Deng, Jing ;

Seymour, John F. ;

Tam, Constantine ;

Kim, Su Young ;

Fein, Joshua ;

Yu, Lijian ;

Brown, Jennifer R. ;

Westerman, David ;

Si, Eric G. ;

Majewski, Ian J. ;

Segal, David ;

Enschede, Sari L. Heitner ;

Huang, David C. S. ;

Davids, Matthew S. ;

Letai, Anthony ;

Roberts, Andrew W. .

BLOOD, 2016, 127 (25) :3215-3224

[3]

[Anonymous], 2015, BLOOD

[4] MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study [J].

Copie-Bergman, Christiane ;

Cuilliere-Dartigues, Peggy ;

Baia, Maryse ;

Briere, Josette ;

Delarue, Richard ;

Canioni, Danielle ;

Salles, Gilles ;

Parrens, Marie ;

Belhadj, Karim ;

Fabiani, Bettina ;

Recher, Christian ;

Petrella, Tony ;

Ketterer, Nicolas ;

Peyrade, Frederic ;

Haioun, Corinne ;

Nagel, Inge ;

Siebert, Reiner ;

Jardin, Fabrice ;

Leroy, Karen ;

Jais, Jean-Philippe ;

Tilly, Helve ;

Molina, Thierry Jo ;

Gaulard, Philippe .

BLOOD, 2015, 126 (22) :2466-2474

[5] Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [J].

Davids, Matthew S. ;

Roberts, Andrew W. ;

Seymour, John F. ;

Pagel, John M. ;

Kahl, Brad S. ;

Wierda, William G. ;

Puvvada, Soham ;

Kipps, Thomas J. ;

Anderson, Mary Ann ;

Salem, Ahmed Hamed ;

Dunbar, Martin ;

Zhu, Ming ;

Peale, Franklin ;

Ross, Jeremy A. ;

Gressick, Lori ;

Desai, Monali ;

Kim, Su Young ;

Verdugo, Maria ;

Humerickhouse, Rod A. ;

Gordon, Gary B. ;

Gerecitano, John F. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08) :826-833

[6] How I treat double-hit lymphoma [J].

Friedberg, Jonathan W. .

BLOOD, 2017, 130 (05) :590-596

[7] Multiple Functions of BCL-2 Family Proteins [J].

Hardwick, J. Marie ;

Soane, Lucian .

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2013, 5 (02)

[8] Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation [J].

Herrera, Alex F. ;

Mei, Matthew ;

Low, Lawrence ;

Kim, Haesook T. ;

Griffin, Gabriel K. ;

Song, Joo Y. ;

Merryman, Reid W. ;

Bedell, Victoria ;

Pak, Christine ;

Sun, Heather ;

Paris, Tanya ;

Stiller, Tracey ;

Brown, Jennifer R. ;

Budde, Lihua E. ;

Chan, Wing C. ;

Chen, Robert ;

Davids, Matthew S. ;

Freedman, Arnold S. ;

Fisher, David C. ;

Jacobsen, Eric D. ;

Jacobson, Caron A. ;

LaCasce, Ann S. ;

Murata-Collins, Joyce ;

Nademanee, Auayporn P. ;

Palmer, Joycelynne M. ;

Pihan, German A. ;

Pillai, Raju ;

Popplewell, Leslie ;

Siddiqi, Tanya ;

Sohani, Aliyah R. ;

Zain, Jasmine ;

Rosen, Steven T. ;

Kwak, Larry W. ;

Weinstock, David M. ;

Forman, Stephen J. ;

Weisenburger, Dennis D. ;

Kim, Young ;

Rodig, Scott J. ;

Krishnan, Amrita ;

Armand, Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :24-+

[9] Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis [J].

Howlett, Christina ;

Snedecor, Sonya J. ;

Landsburg, Daniel J. ;

Svoboda, Jakub ;

Chong, Elise A. ;

Schuster, Stephen J. ;

Nasta, Sunita Dwivedy ;

Feldman, Tatyana ;

Rago, Allison ;

Walsh, Kristy M. ;

Weber, Scott ;

Goy, Andre ;

Mato, Anthony .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (04) :504-514

[10] The BCL6 proto-oncogene:: a leading role during germinal center development and lymphomagenesis [J].

Jardin, Fabrice ;

Ruminy, Philippe ;

Bastard, Christian ;

Tilly, Herve .

PATHOLOGIE BIOLOGIE, 2007, 55 (01) :73-83

← 1 2 3 4 →